Biocon’s novel drug pipeline which has an ophthalmology molecule, QPI-1007, is entering clinical trial phase. QPI-1007 is for ocular neuroprotection in NAION and acute angle closure glaucoma. In mid-December 2013, the company entered into a licensing and collaboration agreement for the development of a range of siRNA (small interfering RNA) based novel therapeutics with Quark Pharmaceuticals which was researching on QPI-1007.
Glaucoma is a slowly progressing optic neuropathy characterized by the progressive loss of retinal ganglion cells (RGCs) and is the leading cause of blindness worldwide. In India, it is estimated that glaucoma affects 12 million people accounting for 12.8 per cent of the country’s blindness and by 2020, this is expected to reach 16 million.
QPI-1007 completed a phase I/IIa first in human, open label, single-dose, dose escalation, safety, tolerability and pharmacokinetic study conducted at 16 centres in the USA and five centres in Israel.
A team of scientists from Quark and Biocon are jointly engaged in the development of QPI-1007, besides an additional novel pipeline, leveraging the siRNA innovative technology. The collaboration with Quark was to enable Biocon to co-develop, manufacture and commercialize QPI-1007.
In April 2014, the Ophthalmology Times had reported that “Quark Pharmaceuticals one intravitreal injection of QPI-1007 to treat non-arteritic anterior ischemic optic neuropathy (NAION) was safe with no serious adverse events in a phase I trial. “This is for the first time that the company has looked at an ophthalmology molecule. It is a new initiative and would be too early to comment on,” Kiran Mazumdar-Shaw, chairman and managing director said in her Q1 results con-call to a Pharmabiz query.
Subscribe to PharmaTutor News Alerts by Email >>
